Chronic Myeloid Leukemia (CML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Chronic Myeloid Leukemia (CML) Market Outlook

Thelansis’s “Chronic Myeloid Leukemia (CML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Myeloid Leukemia (CML) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Myeloid Leukemia (CML) Overview

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm (MPN) fundamentally driven by the pathognomonic Philadelphia chromosome. Arising from a reciprocal translocation—t(9;22)(q34;q11.2)—this aberration fuses the BCR and ABL1 genes, generating a constitutively active tyrosine kinase that fuels rampant, unregulated myeloid proliferation. While the etiology is predominantly idiopathic, high-dose ionizing radiation remains the sole established environmental risk factor. The disease exhibits a distinct triphasic clinical trajectory: an insidious, often asymptomatic chronic phase (CP) frequently discovered incidentally via marked leukocytosis or splenomegaly, which, if left untreated, inexorably progresses to an accelerated phase (AP) and a rapidly fatal blast crisis (BP). The modern therapeutic paradigm has been entirely revolutionized by targeted tyrosine kinase inhibitors (TKIs)—including frontline agents like imatinib, dasatinib, and nilotinib, as well as subsequent-line therapies like bosutinib, ponatinib, and the novel allosteric inhibitor asciminib. These targeted therapies have dramatically transformed CML into a highly manageable chronic condition, restoring near-normal life expectancies. While allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only definitive biological cure—now largely reserved for TKI-refractory or advanced-phase disease—a significant subset of chronic phase patients who achieve a sustained, deep molecular response on TKIs can now successfully discontinue therapy, successfully achieving a highly durable treatment-free remission (TFR).

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025–2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Chronic Myeloid Leukemia (CML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035


Comments

Post a Comment